Main > > >PROSTATE CANCER. *

Companion Diagnostics.
"Biopsy>Liquid Biopsy CTCs+ctDNA"
(*) Companies; Patents; TradeMarks &
Web-Sites Available on Request.
UpDate: 2018. 06.12.




Diagnostics. Artificial Intelligence (AI)-Powered. Pathology.
EU Approval Date: 2020. 02.27.
(*) Company : Ibex Medical Analytics.
Web-Site: ibex-ai.com/
UpDate: 2020. 03.02.




Diagnostics. Biopsy Rule-Out Blood Test.
(Liquid Biopsy). (A)
USA Launch Date: 2019. 12.16.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 12.22.




Diagnostics. Biopsy Rule-Out Blood Test.
(Liquid Biopsy). (O)
EU Launch Date: 2012. 10.01.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 01.06.




Diagnostics. Biopsy Rule-Out Urine Test.
USA (ex NY) Launch Year: 2017.
USA (NY) Launch Date: 2019. 06.13.
(*) Companies; Patent; TradeMark & Web-
Site Available on Request
UpDate: 2019. 11.18.




Diagnostics. CTC Search Test.
(METASTATIC)
CTC: Circulating Tumor Cells.
USA>Approval Date: 2006. 12.15.
(*) Company : Menarini Silicon
Biosystems
Patent : Expired
TradeMark: CellSearch
Web-Site : www.cellsearchctc.com/
UpDate: 2019. 02.13.




Diagnostics. Total Prostate Specific
Antigen (PSA) Blood Test. In Physician
Office. Result in 10 Minutes.
USA Approval Date: 2019. 02.01.
(*) Company; Patents; TradeMark & Web-
Sites Available on Request.
UpDate: 2020. 01.06.




Paliative TREAT.: Histrelin Acetate Sub-
Cutaneous Implant.
(METASTATIC)
USA Initial Approval Year: 2004.
(*) Company : Endo Pharmaceuticals
Solutions Inc.
TradeMark: Vantas.
Web-Site : www.vantasimplant.com
UpDate: 2018. 12.15.




Paliative TREAT.: Leuprolide Acetate
for Depot Suspension. (E)
(METASTATIC)
ES Launch Date: 2016. 01.14.
(*) Company; Patent; TradeMark & Web-
Sites Available on Request.
UpDate: 2018. 12.15.




Paliative TREAT.: Leuprolide Acetate
for Depot Suspension. (U)
(METASTATIC)
USA Approved.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 12.15.




Prognostics. Information on 3 Genetic Variants found on the BRCA1 and BRCA2 Genes.
USA Approval Date: 2018. 03.06.
UpDate: 2020. 01.20.




Prognostics. Post Prostatectomy.
(*) Company : GenomeDx Biosciences Inc.
TradeMark: Decipher.
Web-Site : deciphertest.com
UpDate: 2018. 12.12.




Prognostics. Prostate Genetic Score.
Hispanic Validation Date: 2019. 12.02.
(*) Company; Patent; TradeMark & Web-
Sites Available on Request.
UpDate: 2020. 01.12.




Prostatectomy. Magnetic Surgical System.
USA Approval Date: 2019. 04.30.
(*) Company; Patents; TradeMark & Web-
Sites Available on Request.
UpDate: 2019. 12.30.




Recurrence. Diagnostics. PET Imaging
Agent: Fluciclovine F 18 Inj.
PET: Positron Emission Tomography.
EU Approval Date : 2017. 05.23.
USA Approval Date: 2016. 05.27.
(*) Companies; Patents; TradeMark &
Web-Site Available on Request.
UpDate: 2018. 12.16.




TREAT.: Abiraterone Acetate Tab. (I)
[METASTATIC; Castration Resistant (CR)]
USA Approval Date: 2018. 05.23.
(*) Company; Patent & TradeMark Avai-
lable on Request.
UpDate: 2018. 12.11.




TREAT.: Abiraterone Acetate Tab. (U)
[METASTATIC; Castration Resistant (CR)]
[METASTATIC; High Risk; Castration Sen-
sitive (CS)].
+Prednisone (Steroid).
Androgen AntAgonist (CCYP17A1 Modulator.
EU Approval Date : 2011. 09.07.
USA Approval Date: 2011. 04.28.
(*) Companies; Patent; TradeMark & Web-
Sites Available on Request.
UpDate: 2018. 12.11.




TREAT.: ApalutAmide Tablets.
[METASTATIC; Castration-Sensitive (CS)]
Androgen Receptor Inhibitor.
USA Approval Date: 2019. 09.17.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 12.29.




TREAT.: ApalutAmide Tablets.
[NON-METASTATIC; Castration-Resistant
(CR)].
Androgen Receptor Inhibitor.
CA Approval Date : 2018. 07.05.
USA Approval Date: 2018. 02.14.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 12.16.




TREAT.: BicalutAmide Tab.+
(METASTATIC; Stage D2).
+Luteinizing Hormone-Releasing Hormone
(LHRH) Analog.
USA Initial Approval: 1995.
(*) Company (USA): Ani Pharma.
Company (EMEA): Juvise Pharma.
www.juvisepharmaceuticals.com/
Licensor : AstraZeneca
Patent : Expired
TradeMark: Casodex
UpDate: 2019. 12.21.




TREAT.: BrachyTherapy. I-125 Seeds.
(NON-METATASTATIC).
JP Approval Date: 2016. 03.
JP Launch Date: 2016. 06.03.
(*) Companies; Patents; TradeMark &
Web-Site Available on Request.
UpDate: 2018. 12.12.




TREAT.: BrachyTherapy. Low Dose Rate
(LDR) BrachyTherapy.
USA Approval Year: 2013.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 11.25.




TREAT.: BrachyTherapy. MRI Marker>
(NON-METASTATIC)
>High Dose Rate (HDR) BrachyTherapy>
Temporary. PRIOR BrachyTherapy Use.
USA 1st Patient: 2019. 09.11.
USA Clearance : 2018. 05.08.
>Low Dose Rate (LDR) BrachyTherapy>
Permanent. POST BrachyTherapy Use
USA 1st Patient: 2014. 04.07.
USA Clearance : 2013. 12.06.
(*) Companies; Patents; TradeMarks &
Web-Sites Available on Request.
UpDate: 2019. 11.20.




TREAT.: CabaziTaxel Inj.+>
[METASTATIC; Castration Resistant (CR);
Hormone Resistant (HR)].
+Prednisone
>Worsened>Treat. .. DoceTaxel.
EU Approval Date : 2011. 03.17.
USA Approval Date: 2010. 06.17.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 12.13.




TREAT.: Darolutamide Tab.
[NON-METASTATIC; CASTRATION RESISTANT (CR)].
USA Approval Date: 2019. 07.30.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 11.18.




TREAT.: Degarelix for Inj.
(METASTATIC)
EU Approval Date : 2009. 02.20.
USA Approval Date: 2008. 12.24.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 12.14.




TREAT.: DoceTaxel Inj.
[METASTATIC; Hormone Refractory (HR)]
+Prednisone (Steroid)
USA Initial Approval Year: 1996.
(*) Company : Sanofi Aventis US LLC.
Patent : Expired
TradeMark: Taxotere
UpDate: 2018. 12.11.




TREAT.: DoceTaxel Inj. Alcohol-Free.
[METASTATIC; Hormone Refractory (HR)].
+Prednisone (Steroid)
USA Approval Date: 2015. 12.28.
USA Launch Date: 2016. 02.02.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 12.11.




TREAT.: EnzalutAmide Capsules.>
[METASTATIC; Castration Resistant (CR)]
>No Longer Responds to a medical or
surgical treatment that lowers
testosterone
Androgen Receptor AntAgonist
CA Approval Date: 2019. 01.14.
USA Approval Date: 2012. 08.31.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 01.15.




TREAT.: EnxalutAmide Capsules.
[METASTATIC; Castration Sensitive (CS)]
Androgen Receptor AntAgonist.
JP Approval Date: 2020. 05.29.
USA Approval Date: 2019. 12.17.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 09.15.




TREAT.: EnzalutAmide Capsules.
[NON-METASTATIC; Castration Resistant
(CR)]
CA Approval Date: 2019. 01.14.
CN Approval Date: 2020. 11.06.
USA Approval Date: 2018. 07.13.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2021. 02.10.




TREAT.: Goserelin Acetate Implant. Brand
+FlutAmide.
Management of METASTATIC Stage T2b-T4 (Stage B2-C) prostate cancer. Treatment with ZOLADEX and flutamide should start 8 weeks before the start of radiation therapy and continue during radiation therapy.
USA Approval Date: 1997. 06.27.
(*) Company : TerSera Therapeutics.
Patent : Expired.
TradeMark: Zoladex.
Web-Site :
www.zoladex.com/index.html
UpDate: 2018. 12.15.




TREAT.: NilutAmide Tablets. Generic.
(METASTATIC; Stage D2)
+Surgical Castration.
USA Launch Date: 2016. 07.18.
(*) Company: Ani Pharma.
UpDate: 2018. 12.15.




TREAT.: Olaparib Tablets.
(METASTATIC; CR; HRR Mutated).
>Companion Diagnostics>
CA Approval Date: 2020. 11.25
JP Approval Date: 2020. 12.28
USA Approval Date: 2020. 05.20
(*) Companies; Patents; TradeMark &
Web-Site Available on Request.
UpDate: 2021. 02.10.




TREAT.: RadioTherapy (RT). Tissue Mar-
ker. Rectum RT Exposure MInimization.
JP Approval Date: 2017. 05.31.
JP Launch Date : 2018. 07.02.
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 07.17.




TREAT.: Relugolix Tablets.>
(Advanced)
GnRH AntAgonist.
Advanced>
>when it has spread or come back after
initial treatment and may include
biochemical recurrence (rising
prostate-specific antigen in the
absence of metastatic disease on
imaging), locally advanced disease, or
metastatic disease.
USA Approval Date: 2020. 12.18.
USA Launch Date: 2021. 01.05.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2021. 02.18.




TREAT.: Rucaparib Tablets.>
(METASTATIC; CR; BRCA 1/2 Mutant)
>Treated With Androgen Receptor-Directed
Therapy And A Taxane-Based CT.
Companion Diagnostics>
>USA Approval Date: 2020. 08.26.
USA Approval Date: 2020. 05.15.
(*) Companies; Patents; TradeMarks &
Web-Site Available on Request.
UpDate: 2020. 09.21.




TREAT.: Sipuleucel-T Vaccine.
(METASTATIC)
USA Approval Date: 2010. 04.29.
(*) Company : Dendreon Pharmaceuticals
Patent : Expired
TradeMark: Provenge
Web-Site : www.provenge.com
UpDate: 2018. 12.15.




TREAT.: Thermal UltraSound (US) Ablation
+MRI+Temperature Feedback.
(NON-MET.)
CA Approval Date : 2019. 11.25.
EU Approval Date : ?
USA Approval Date: 2019. 08.15.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 01.09.


>PROSTATE CANCER. *'s products
This section has no products